Atlas FDA

THERASCREEN EGFR RGQ PCR KIT

FDA premarket approval P120022/S013 · decided 2016-09-07

Approval details

PMA number
P120022
Supplement
S013
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
THERASCREEN EGFR RGQ PCR KIT
Generic name
Somatic gene mutation detection system
Applicant
QIAGEN GmbH
Date received
2016-08-10
Decision date
2016-09-07
Days to decision
28 days
Decision code
OK30
Product code
OWD
Advisory committee
Pathology
Expedited review
No
Location
Hilden
Statement
Change to the mean Ct specification for the positive control (PC) at the final kit release stage and the target Ct value for the manufacturing adjustment process for the L861Q reaction mix.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
QIAstat-Dx BCID GPF Plus AMR Panel (K254194)QIAGEN GmbH2026-08-06
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K254032)QIAGEN GmbH2026-03-09
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K252329)QIAGEN GmbH2025-10-22
QIAstat-Dx Respiratory Panel Plus; QIAstat-Dx Respiratory Panel Mini (K250080)QIAGEN GmbH2025-08-27
QIAstat-Dx GI Panel 2 Mini B (K250324)QIAGEN GmbH2025-02-28
QIAstat-Dx GI Panel 2 Mini B&V (K243813)QIAGEN GmbH2025-01-08
QIAstat-Dx Meningitis/Encephalitis (ME) Panel (K242256)QIAGEN GmbH2024-10-29
QIAstat-Dx Respiratory Panel Mini (K242353)QIAGEN GmbH2024-10-25